Theranexus Stock price

Equities

ALTHX

FR0013286259

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:35:28 2024-03-28 pm EDT 5-day change 1st Jan Change
1.152 EUR -2.37% Intraday chart for Theranexus +7.66% +2.86%
Sales 2021 602 648.8 Sales 2022 415K 447K Capitalization 9.36M 10.08M
Net income 2021 -8M -8.62M Net income 2022 -6M -6.47M EV / Sales 2021 25,622 x
Net cash position 2021 7.2M 7.76M Net cash position 2022 4.22M 4.55M EV / Sales 2022 12.4 x
P/E ratio 2021
-3.05 x
P/E ratio 2022
-1.42 x
Employees 19
Yield 2021 *
-
Yield 2022
-
Free-Float 78.95%
More Fundamentals * Assessed data
Dynamic Chart
Theranexus: CEO takes over as Chairman of the Board CF
Certain Ordinary Shares of Theranexus Société Anonyme are subject to a Lock-Up Agreement Ending on 11-JAN-2024. CI
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Theranexus Société Anonyme announced that it has received €2.470412 million in funding CI
Global markets live: Lucid, Under Armour, Coty, PayPal, Western Digital... Our Logo
Theranexus and BBDF Win FDA Approval on Efficacy Endpoints for the Phase III Trial to Evaluate Batten-1 in CLN3 Batten Disease CI
Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Theranexus Announces the Initial Results of Their Phase I/II Clinical Trial for Juvenile Batten Disease CI
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Theranexus Société Anonyme Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Theranexus Société Anonyme Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Theranexus : to Begin Early-Stage Study of Rare Disease Drug MT
Theranexus : Creates Drug Development JV; Stock Down4% MT
Theranexus Reports Earnings Results for the Full Year Ended December 31, 2018 CI
Theranexus to Present Latest Findings on the Role of Astroglial Connexins in the Efficacy of THN201 in Neurocognitive Disorders Linked to Alzheimer's Disease CI
More news
1 day-2.37%
1 week+7.66%
Current month+75.88%
1 month+67.69%
3 months+0.52%
6 months-1.20%
Current year+2.86%
More quotes
1 week
1.03
Extreme 1.03
1.30
1 month
0.63
Extreme 0.63
1.35
Current year
0.63
Extreme 0.63
1.35
1 year
0.63
Extreme 0.63
3.18
3 years
0.63
Extreme 0.63
15.58
5 years
0.63
Extreme 0.63
23.60
10 years
0.63
Extreme 0.63
23.60
More quotes
Managers TitleAgeSince
Founder - 13-03-18
Founder - 13-03-18
Director of Finance/CFO - 16-12-31
Members of the board TitleAgeSince
Director/Board Member 63 18-12-12
Director/Board Member 50 17-09-25
Founder - 13-03-18
More insiders
Date Price Change Volume
24-03-28 1.152 -2.37% 19,621
24-03-27 1.18 -1.67% 24,336
24-03-26 1.2 +10.50% 144,541
24-03-25 1.086 +1.50% 5,292
24-03-22 1.07 0.00% 4,005

Real-time Euronext Paris, March 28, 2024 at 12:35 pm EDT

More quotes
Theranexus is an innovative biopharmaceutical company that emerged from the French Atomic Energy Commission (CEA) and specializes in the treatment of neurological diseases and pioneer in the development of drug candidates targeting both neurons and glial cells. Theranexus has a unique platform for the identification and characterization of innovative therapy drug candidates in rare neurological disorders and a first drug candidate in clinical development for Batten disease.
More about the company
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.152 EUR
Average target price
4 EUR
Spread / Average Target
+247.22%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Theranexus - Euronext Paris